INAB Company Profile and Key Details

INAB has shown sold momentum, gaining 8.26% over the past week and 14.01% over the past quarter, though year-to-date performance is up 0.85%. Short-term trend indicators are bullishly aligned (SMA20 -5.73%, SMA50 -14.09%, SMA200 -24.67%). The stock’s 14-day RSI is 42.86 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -80.31% below its high and over 46.15% above its low. Average 10-day trading volume of 25.78 thousand shares is below the 3-month average of 286.21 thousand, indicating normal recent market interest.

IN8bio, Inc. generated EPS of -$6.63 over the past year. Five-year average earnings growth is -13.23%. Wall Street analysts project EPS growth of 53.74% annually over the next five years. The latest quarter delivered EPS of -$0.85. The next quarter is forecast at -$0.64. Next year's EPS is expected at $33.15. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 248.84% upside. The low target suggests 248.84% downside. The mean target is $6.00. This offers 248.84% upside. IN8bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -29.17%. The prior quarter beat by -17.33%. Over the last six quarters, Apple has recorded several small beats. These include 18.75% in August 08, 2024.

IN8bio, Inc. has 4.54 million shares outstanding. The public float is 4.18 million shares, elevated short interest at 3.68% of float. This equals 110.16 thousand shares. The short ratio is 0.75 days. Institutional investors hold 20.42% of the float. Insiders own 5.56%. Transcend Partners Opportunity Fund LLC holds 4.11 million shares, Cavu Advisors, LLC has 3.65 million shares and BIOS Advisors GP, LLC has 3.61 million shares.

IN8bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.11. This means the shares are trading above this model’s fair value.

IN8bio, Inc. (NASDAQ:INAB) closed at $1.72 USD, losing -$0.02 (-1.15%) from the previous close of $1.74. The stock is currently mid-range between its 52-week high and low $1.17 and $7.86. With a market capitalization of about $7.97 million, IN8bio, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 280.09 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, IN8bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tai-Wei, the company employs approximately 18 people and listed since July 30, 2021. IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers.

IN8bio, Inc. trades at a P/E ratio of -0.37, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.59 suggesting the stock is closer to book value. The P/FCF stands at -0.54, also above market averages.

IN8bio, Inc. (NASDAQ:INAB) shares are flat 0.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows IN8bio, Inc. trading at a premium to the broader market with a P/E of -0.37. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.01, suggesting 423.84% upside. Our AI forecast model points to short-term weakness (-13.95% over two weeks), a medium-term fall (-54.07% over three months), and a longer-term gain (576.16% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that IN8bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.95%, with price expected at $1.48 by March 20, 2026, within a range of $1.33 to $1.64 3-Month Outlook: Projected fall of -54.07%, reaching $0.79 by June 04, 2026, with a range of $0.55 to $0.92. 1-Year Outlook: Projected gain of 576.16%, with price at $11.63 by March 05, 2027, within a range of $11.56 to $11.73.